Edesa Biotech (EDSA) vs Rein Therapeutics (RNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Edesa Biotech (EDSA) has outperformed Rein Therapeutics (RNTX) over the past year, gaining 17.6% versus a loss of 77.2%. Over five years, EDSA leads with a -95.6% price change compared with -97.5% for RNTX. Rein Therapeutics is the larger company by market cap ($29.1 million vs $27.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDSA | RNTX |
|---|---|---|
| Share price | $2.00 | $0.3369 |
| Market cap | $27.02M | $29.06M |
| 1-day change | -8.05% | -8.38% |
| YTD return | +40.85% | -70.96% |
| 1-year return | +17.65% | -77.24% |
| 5-year return | -95.63% | -97.47% |
| EPS (TTM) | $-1.72 | $-1.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-7.19M | $-49.87M |
| 52-week high | $20.32 | $2.10 |
| 52-week low | $0.72 | $0.284 |
| Distance from 52-week high | -90.16% | -83.96% |
| Analyst consensus | none | none |
| Avg. price target upside | +716.50% | +1680.94% |
| Average volume | 1.45M | 586.68K |
| Shares outstanding | 13.51M | 86.27M |
| Employees | 17 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed RNTX by 94.9 percentage points over the past year.
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About Rein Therapeutics
RNTX stock →Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
EDSA vs RNTX FAQ
Which is bigger, Edesa Biotech or Rein Therapeutics?
Rein Therapeutics (RNTX) is larger, with a market capitalization of $29.06M compared with $27.02M for Edesa Biotech (EDSA).
Which stock has performed better over the past year, EDSA or RNTX?
EDSA returned +17.65% over the past 12 months, compared with -77.24% for RNTX (price return, excluding dividends). Past performance does not predict future results.
Are Edesa Biotech and Rein Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.